MPC-3100 is primarily utilized in the field of oncology as a heat shock protein 90 (Hsp90) inhibitor. It is being investigated for its potential to treat various types of cancers by disrupting the function of Hsp90, a protein that plays a critical role in the stabilization and activation of numerous client proteins involved in cancer cell growth and survival. By inhibiting Hsp90, MPC-3100 aims to degrade these client proteins, thereby inhibiting tumor progression and promoting cancer cell death. Clinical studies are ongoing to evaluate its efficacy and safety in patients with advanced or refractory cancers, particularly in cases where traditional therapies have failed. Its development represents a targeted approach to cancer treatment, offering hope for improved outcomes in challenging malignancies.